Skip to main content

Advertisement

SpringerLink
Log in

Analysis of the Survival Period in Resectable Stage IV Gastric Cancer

  • Published:
Annals of Surgical Oncology Aims and scope Submit manuscript

Abstract

Background: Patients with stage IV gastric cancer usually have a poor prognosis, but some patients with resectable cancer survive for more than 5 years. We aimed to study the correlation of protein expression and survival in resectable stage IV gastric cancer.

Patients and Methods: Tissue samples of 42 patients with resectable stage IV gastric cancer were stained immunohistochemically for the mutant p53 protein and heat shock protein-27 (hsp27). The correlation between protein expression and clinicopathological factors was investigated. Furthermore, prognostic value of each factor was analyzed.

Results: Univariate analysis showed that pN factors (Japanese classification, P = .028; International Union Against Cancer classification, P = .024), blood vessel invasion (P = .043), hsp27 overexpression (P = .019), and the index of p53 and hsp27 overexpression (P = .0026) had a prognostic influence. Only Lauren classification, however, revealed the prognostic influence in multivariate analysis (P = .046).

Conclusions: These results suggest that immunostaining of tumor specimens for p53 and hsp27 and clinicopathological analysis may help predict the survival of patients with resectable stage IV gastric cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
$34.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

REFERENCES

  1. Kodera Y, Yamamura Y, Shimizu Y, et al. Metastatic gastric lymph node rate is a significant prognostic factor for resectable stage IV stomach cancer. J Am Coll Surg 1997; 185: 65–9.

    CAS  PubMed  Google Scholar 

  2. Kakeji T, Maehara Y, Tomoda M, et al. Long-term survival of patients with stage IV gastric carcinoma. Cancer 1998; 82: 2307–11.

    CAS  PubMed  Google Scholar 

  3. Lim BH, Soong R, Grieu F, Robbins PD, House AK, Iacopetta BJ. p53 accumulation and mutation are prognostic indicators of poor survival in human gastric carcinoma. Int J Cancer 1996; 69: 200–4.

    CAS  PubMed  Google Scholar 

  4. Ichiyoshi Y, Oiwa H, Tomisaki S, et al. Overexpression of p53 is associated with growth pattern and prognosis in advanced gastric cancer. Hepatogastroenterology 1997; 44: 546–53.

    CAS  PubMed  Google Scholar 

  5. Monig SP, Eidt S, Zirbes TK, Stippel D, Baldus SE, Pichlmaier H. p53 expression in gastric cancer: Clinicopathological correlation and prognostic significance. Dig Dis Sci 1997; 42: 2463–7.

    CAS  PubMed  Google Scholar 

  6. Maehara Y, Tomoda M, Hasuda S, et al. Prognostic value of p53 protein expression for patients with gastric cancer—A multivariate analysis. Br J Cancer 1999; 79: 1255–61.

    CAS  PubMed  Google Scholar 

  7. Nakata B, Chung KH, Ogawa M, et al. p53 protein overexpression as a predictor of the response to chemotherapy in gastric cancer. Surg Today 1998; 28: 595–8.

    CAS  PubMed  Google Scholar 

  8. Martin HM, Filipe MI, Morris RW, Lane DP, Silvestre F. p53 expression and prognosis in gastric carcinoma. Int J Cancer 1992; 50: 859–62.

    CAS  PubMed  Google Scholar 

  9. Joypaul BV, Hopwood D, Newman EL, et al. The prognostic significance of the accumulation of p53 tumor-suppressor gene protein in gastric adenocarcinoma. Br J Cancer 1994; 69: 943–6.

    CAS  PubMed  Google Scholar 

  10. Gurel S, Dolar E, Yerci O, et al. Expression of p53 protein and prognosis in gastric carcinoma. J Int Med Res 1999; 27: 85–9.

    CAS  PubMed  Google Scholar 

  11. Langdon SP, Rabiasz GJ, Hirst GL, et al. Expression of the heat shock protein HSP27 in human ovarian cancer. Clin Cancer Res 1995; 1: 1603–9.

    CAS  PubMed  Google Scholar 

  12. Arts HJ, Hollema H, Lemstra W, et al. Heat-shock-protein-27 (hsp27) expression in ovarian carcinoma: Relation in response to chemotherapy and prognosis. Int J Cancer 1999; 21: 234–8.

    Google Scholar 

  13. Vargas-Roig LM, Gago FE, Tello O, Aznar JC, Ciocca DR. Heat shock protein expression and drug resistance in breast cancer patients treated with induction chemotherapy. Int J Cancer 1998; 79: 468–75.

    CAS  PubMed  Google Scholar 

  14. Mehlen P, Mehlen A, Guillet D, Preville X, Arrigo AP. Tumor necrosis factor-α-induced changes in the phosphorylation, cellular localization, and oligomerization of human hsp27, a stress protein that confers cellular resistance to this cytokine. J Cell Biochem 1995; 58: 248–59.

    CAS  PubMed  Google Scholar 

  15. Wang G, Klostergaard J, Khodadadian M, et al. Murine cells transfected with human hsp27 cDNA resist TNF-induced cytotoxicity. J Immunother 1996; 19: 9–20.

    CAS  Google Scholar 

  16. Mehlen P, Osthoff KS, Arrigo AP. Small stress proteins as novel regulators of apoptosis. J Biol Chem 1996; 271: 16510–4.

    CAS  PubMed  Google Scholar 

  17. Guenal I, Fraisse CS, Gaumer S, Mignotte B. Bcl-2 and Hsp27 act at different levels to suppress programmed cell death. Oncogene 1997; 15: 347–60.

    CAS  PubMed  Google Scholar 

  18. Kwon SJ, Kim GS. Prognostic significance of lymph node metastasis in advanced carcinoma of the stomach. Br J Surg 1996; 83: 1600–3.

    CAS  PubMed  Google Scholar 

  19. Japanese Research Society for Gastric Cancer. Japanese Classification of Gastric Carcinoma. Tokyo: Kanehara Publishers, 1995.

  20. Sobin LH, Wittekind C. UICC TNM Classification of Malignant Tumours 5th ed New York: Wiley-Liss 1997.

    Google Scholar 

  21. Lauren P. The two histological main types of gastric carcinomas: Diffuse and so-called intestinal-type carcinoma. Acta Pathol Microbiol Immunol Scand 1965; 64: 31–49.

    CAS  Google Scholar 

  22. Hurlimann J, Saraga EP. Expression of p53 protein in gastric carcinomas. Association with histologic type and prognosis. Am J Surg Pathol 1994; 18: 1247–53.

    Article  CAS  PubMed  Google Scholar 

  23. Gabbert HE, Mueller W, Schneiders A, Meier S, Hommel G. The relationship of p53 expression to the prognosis of 418 patients with gastric carcinoma. Cancer 1995; 76: 720–6.

    CAS  PubMed  Google Scholar 

  24. Victorzon M, Nordling S, Haglund C, Lundin J, Roberts PJ. Expression of p53 protein as a prognostic factor in patients with gastric cancer. Eur J Cancer 1996; 32A: 215–20.

    CAS  PubMed  Google Scholar 

  25. Muller W, Borchard F. Prognostic influence of p53 expression in gastric cancer. J Pathol 1996; 178: 255–8.

    CAS  PubMed  Google Scholar 

  26. Garrido C, Ottavi P, Fromentin A, et al. HSP27 as a mediator of confluence-dependent resistance to cell death induced by anticancer drugs. Cancer Res 1997; 57: 2661–7.

    CAS  PubMed  Google Scholar 

  27. Ciocca DR, Fuqua SA, Lock-Lim S, Toft DO, Welch WJ, McGuire WL. Response of human breast cancer cells to heat shock and chemotherapeutic drugs. Cancer Res 1992; 52: 3648–54.

    CAS  PubMed  Google Scholar 

  28. WuW, Welsh MJ. Expression of the 25-kDa heat-shock protein (HSP27) correlates with resistance to the toxicity of cadmium chloride, mercuric chloride, cis-platinum(II)-Diammine Dichloride, or sodium arsenite in mouse embryonic stem cells transfected with sense or antisense HSP27 cDNA. Toxicol Appl Pharmacol 1996; 141: 330–9.

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Departments of Surgery II, Oita Medical University, Japan

    Shinsuke Takeno MD, PhD, Tsuyoshi Noguchi MD, PhD & Yuzo Uchida MD, PhD

  2. Department of Pathology I, Oita Medical University, Japan

    Ryuichi Kikuchi MD, PhD & Shigeo Yokoyama MD, PhD

  3. Departments of Surgery II, Oita Medical University, Idaigaoka 1-1, Hasama-machi, Oita, 879-5593, Japan

    Shinsuke Takeno MD, PhD & Tetsuro Sato MD

Authors
  1. Shinsuke Takeno MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Tsuyoshi Noguchi MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ryuichi Kikuchi MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Tetsuro Sato MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Yuzo Uchida MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Shigeo Yokoyama MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Takeno, S., Noguchi, T., Kikuchi, R. et al. Analysis of the Survival Period in Resectable Stage IV Gastric Cancer. Ann Surg Oncol 8, 215–221 (2001). https://doi.org/10.1007/s10434-001-0215-1

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10434-001-0215-1

Key Words:

Search

Navigation